191 reports of this reaction
4.0% of all MECLIZINE HCL reports
#2 most reported adverse reaction
DIZZINESS is the #2 most commonly reported adverse reaction for MECLIZINE HCL, manufactured by Rising Pharma Holdings, Inc.. There are 191 FDA adverse event reports linking MECLIZINE HCL to DIZZINESS. This represents approximately 4.0% of all 4,811 adverse event reports for this drug.
Patients taking MECLIZINE HCL who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among MECLIZINE HCL users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for MECLIZINE HCL:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 191 FDA reports for MECLIZINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 4.0% of all adverse event reports for MECLIZINE HCL, making it one of the most commonly reported side effect.
If you experience dizziness while taking MECLIZINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.